Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma

Melanoma Research

Volumn 8, Issue 6, 1998, Pages 565-572

  Semb, K A ^a   Aamdal, S ^a   Bohmann, T ^a   Lucas, C ^b   Gerard, B ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cisplatin; Clinical trial; Combination chemotherapy; Fotemustine; Malignant melanoma; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FOTEMUSTINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; OTOTOXICITY; PRIORITY JOURNAL; SKIN CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032415531     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199812000-00012     Document Type: Article

References (28)

1. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 1976; 60: 165-176.
2. Balch CM, Reintgen D, Kirkwood JM, Houghton AN, Peters LJ, Kian Ang K. Cutaneous melanoma. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven Publishers, 1997: 1947-1994.
3. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50: 553-556.
4. DelPrete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbaxine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405.
5. Fierro MT, Bertero M, Novelli M, Appino A, Doveil GC, Colonna S, Bernengo MG. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993; 3: 127-131.
6. Reinigen D, Saba H. Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. Semin Surg Oncol 1993; 9: 251-255.
7. Berd D, McLaughlin CJ, Hart E, Wiebe VJ, Mastrangelo MJ, Bellet RE. Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1991; 10: 291(abstract).
8. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-1295.
9. Regal-Huguet F, Gaspard MH, Attal M, Giroux B, Lucas C, Pris J. Pharmacokinetique clinique de la fotemustine haute dose avec ètude du passage de la barrièr hematomenigie. Bull Cancer Paris 1990; 77: 599-605.
10. Jacquillat C, Khayat D, Banzet P, Weil M, Avril MF, Fumoleau P, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, Bugat R, Montcuquet P, Audhuy B, Cupissol D, Lauvin R, Grosshans E, Vilmer C, Prache C, Bizzari JP. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878.
11. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-1360.
12. Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur J Cancer 1992; 28: 447-450.
13. Gordon BH, Richards RP, Hiley MP, Gray AJ, Ings RM, Campbell DB. A new method for the measurement of nitrosoureas in plasma: an HPLC procedure for the measurement of fotemustine kinetics. Xenobiotica 1989; 19: 329-339.
14. Iliadis A, Launay-Iliadis MC, Lucas C, Fety R, Lokiec F, Tranchand B, Milano G. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Eur J Cancer 1996; 32A: 455-460.
15. McClay EF, McClay ME. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 1994; 12: 617-626.
16. Kleeberg UR, Engel E, Israels P, Brocker EB, Tilgen W, Kennes C, Gerard B, Lejeune F, Glabbeke MV, Lentz MA. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995; 5: 195-200.
17. Richards JM, Gilewski TA, Ramming K, Mitchel B, Doane LL, Vogelzang NJ. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992; 69: 427-429.
18. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, Mott L, DelPrete SA, Forcier RJ, Ernstoff MS. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5: 365-369.
19. Saba HI, Klein C, Reinigen D. Management of advanced stage IV metastatic melanoma with a platinol based combination chemotherapy regimen: a University of South Florida and H. Lee Moffitt Melanoma Center study. Proc Am Soc Clin Oncol 1993; 12: 397(abstract).
20. Foshag LJ, Morton DL, Nizze AJ. Response to chemotherapy in melanoma patients after active specific immunotherapy (ASI) with melanoma cell vaccine (MCV). Proc Am Soc Clin Oncol 1993; 12: 397(abstract).
21. Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW III, Fletcher WS, Weiss GR, Unger JM, Sondak VK. Phase II study of carmustine, dacarbazine. cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 664-669.
22. Johnston SRD, Constenla DO, Moore J, Atkinson H. A'Hern RP, Dadian G, Riches PG, Gore mg. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-1286.
23. Donati MB, Gambacorti Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46: 6472-6474.
24. Rümke P, Kleeberg UR, MacKie RM, Lejeune F, Planting PS, Brocker EB, Bierhorst JF, Lentz MA. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res 1992; 2: 153-155.
25. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
26. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bernett K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2083-2090.
27. Falkson CI, Ibrahim J, Kirkwood JM. A randomized phase III trial of dacarbazine (DTIC) versus DTIC + interteron alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC +IFN + TMX in metastatic malignant melanoma: an ECOG trial. Proc Am Soc Clin Oncol 1996; 15: 435(abstract).
28. McClay EF, McClay MET, Jones JA, Winski PJ, Christen RD, Howell SD, Hall PD. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisphitin in patients with metastatic melanoma. Cancer 1997; 79: 1037-1043.